KeyTec® TR-FRET Human IL17AF / IL17RA Binding Assay Kit
Size:
Price: $ Inquiry
CAT.: A1070108D
The KeyTec® TR‑FRET Human IL‑17AF/IL‑17RA Binding Assay Kit is designed for screening small‑molecule inhibitors, peptides, or antibodies that block the interaction between IL‑17AF and IL‑17RA proteins. This kit is based on KeyTec® TR‑FRET technology, offering advantages such as simple and rapid operation and high accuracy.
As illustrated in the schematic diagram below, KeyTec® TR‑FRET Solar Eu1‑conjugated Streptavidin (abbreviated as SA) is pre‑complexed with biotinylated homodimeric Human IL‑17AF protein (AVI‑Biotin). The IL‑17RA protein is conjugated with KeyTec® TR‑FRET LA2 acceptor. When IL‑17AF binds to IL‑17RA, Solar Eu and LA are brought into close proximity, enabling energy resonance transfer between the donor and acceptor upon external light excitation. The degree of interaction between IL‑17AF and IL‑17RA is determined by measuring the signal intensity at 665 nm. Compounds, peptides, or antibodies that block the IL‑17AF/IL‑17RA interaction will result in a decrease in the TR‑FRET signal.
Validation results with the standard blocker Bimekizumab
Test results of the blocker Bimekizumab in different matrix solutions
Test results at different incubation times
| CAT. | Description | Size |
| A1070108D | KeyTec® TR-FRET Human IL17AF / IL17RA Binding Assay Kit | 100 tests |
|
• 1 vial of 20 µL IL17 / IL17RA binding Standard • 1 vial of 5 µL Biotin- IL17AF& SA- Solar Eu Mix • 1 vial of 5 µL IL17RA-LA • 2 vials of 2 mL Binding Assay Diluent Buffer • 1 vial of 2 mL Solar Eu Detection Buffer |
||
| Certificate of Analysis | Limitations | Storage Conditions |
| LOT. | For research use only |
-60 ℃及以下 |
The KeyTec® TR‑FRET Human IL‑17AF/IL‑17RA Binding Assay Kit is designed for screening small‑molecule inhibitors, peptides, or antibodies that block the interaction between IL‑17AF and IL‑17RA proteins. This kit is based on KeyTec® TR‑FRET technology, offering advantages such as simple and rapid operation and high accuracy.
As illustrated in the schematic diagram below, KeyTec® TR‑FRET Solar Eu1‑conjugated Streptavidin (abbreviated as SA) is pre‑complexed with biotinylated homodimeric Human IL‑17AF protein (AVI‑Biotin). The IL‑17RA protein is conjugated with KeyTec® TR‑FRET LA2 acceptor. When IL‑17AF binds to IL‑17RA, Solar Eu and LA are brought into close proximity, enabling energy resonance transfer between the donor and acceptor upon external light excitation. The degree of interaction between IL‑17AF and IL‑17RA is determined by measuring the signal intensity at 665 nm. Compounds, peptides, or antibodies that block the IL‑17AF/IL‑17RA interaction will result in a decrease in the TR‑FRET signal.
Validation results with the standard blocker Bimekizumab
Test results of the blocker Bimekizumab in different matrix solutions
Test results at different incubation times
| CAT. | Description | Size |
| A1070108S | KeyTec® TR-FRET Human IL17AF / IL17RA Binding Assay Kit | 500 tests |
|
• 1 vial of 50 µL IL17 / IL17RA binding Standard • 1 vial of 25 µL Biotin- IL17AF& SA- Solar Eu Mix • 1 vial of 25 µL IL17RA-LA • 1 bottle of 50 mL (A1010001S) Binding Assay Diluent Buffer • 1 bottle of 30 mL (A1010002S) Solar Eu Detection Buffer |
||
| Certificate of Analysis | Limitations | Storage Conditions |
| LOT. | For research use only |
-60 ℃及以下 |
The KeyTec® TR‑FRET Human IL‑17AF/IL‑17RA Binding Assay Kit is designed for screening small‑molecule inhibitors, peptides, or antibodies that block the interaction between IL‑17AF and IL‑17RA proteins. This kit is based on KeyTec® TR‑FRET technology, offering advantages such as simple and rapid operation and high accuracy.
As illustrated in the schematic diagram below, KeyTec® TR‑FRET Solar Eu1‑conjugated Streptavidin (abbreviated as SA) is pre‑complexed with biotinylated homodimeric Human IL‑17AF protein (AVI‑Biotin). The IL‑17RA protein is conjugated with KeyTec® TR‑FRET LA2 acceptor. When IL‑17AF binds to IL‑17RA, Solar Eu and LA are brought into close proximity, enabling energy resonance transfer between the donor and acceptor upon external light excitation. The degree of interaction between IL‑17AF and IL‑17RA is determined by measuring the signal intensity at 665 nm. Compounds, peptides, or antibodies that block the IL‑17AF/IL‑17RA interaction will result in a decrease in the TR‑FRET signal.
Validation results with the standard blocker Bimekizumab
Test results of the blocker Bimekizumab in different matrix solutions
Test results at different incubation times
| CAT. | Description | Size |
| A1070108L | KeyTec® TR-FRET Human IL17AF / IL17RA Binding Assay Kit | 5,000 tests |
|
• 2 vials of 50 µL IL17 / IL17RA binding Standard • 1 vial of 250 µL Biotin- IL17AF & SA- Solar Eu Mix • 1 vial of 250 µL IL17RA-LA • 1 bottle of 200 mL (A1010001L) Binding Assay Diluent Buffer • 1 bottle of 120 mL (A1010002L) Solar Eu Detection Buffer |
||
| Certificate of Analysis | Limitations | Storage Conditions |
| LOT. | For research use only |
-60 ℃及以下 |
English